JPH0656654A - Tape-shaped pharmaceutical - Google Patents

Abstract

PURPOSE:To provide a tape-shaped pharmaceutical causing no mallaminating between its substrate and tack agent or deformation of the substrate in its application, having air and moisture permeability, excellent in skin followability, with no oozing of the tack agent through the meshes of the substrate during the production and preservation and in the application thereof. CONSTITUTION:In this tape-shaped pharmaceutical one side of whose substrate is provided with a tack agent layer containing a drug, the substrate consists of a warp-knitted fabric comprising 5-400 denier fibers and 10-600g/m<2> in basis weight. The rate of extension of the knitted fabric in the direction of its maximum extensibility is 140-500% per 20mm width under a load of 2kg, while the rate of extension thereof in the direction rectangular to this direction is 100-140% per 30mm width under a load of 2kg.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a tape preparation.

[0002]

2. Description of the Related Art Conventionally, as a support used in a tape preparation, a film or sheet made of synthetic resin, a non-woven fabric or paper made of natural fiber or synthetic fiber, and the like can be mentioned. Examples of the material used for the support include cellulose acetate, ethyl cellulose, polyethylene terephthalate, vinyl acetate-vinyl chloride copolymer, polyamide, ethylene-vinyl acetate copolymer, plasticized polyvinyl chloride, polyethylene, polyvinylidene chloride. Etc.

However, when a synthetic resin film or sheet is used as the support, the breathability and moisture permeability of the support are reduced, so that patients with sensitive skin may have stuffy skin during application of the tape preparation. This causes skin irritation such as erythema and sores.

Further, when a synthetic resin film or sheet having low extensibility, a non-woven fabric, paper or the like is used as the support, these supports cannot follow the expansion and contraction of the skin, and the skin surface is not a little stressed. Therefore, there is a problem in that it causes skin irritation such as erythema and soreness and causes discomfort such as bracing. In particular, when a percutaneous absorption preparation is applied to a joint, there is a problem that the degree of expansion and contraction of the skin is large and peeling is caused due to poor skin followability.

In order to solve the above problems, for example,
A method of using a support having air permeability or moisture permeability and having extensibility can be mentioned. Examples of materials that have been conventionally used as a support include cloths such as woven fabrics, knitted fabrics, braids and nonwoven fabrics, and flexible porous synthetic resin films or sheets. These supports satisfy the air permeability and the moisture permeability, but those satisfying the extensibility are limited to cloths.

However, since most cloths have almost the same stretchability in all directions, when the adhesive layer once formed on the release paper surface is transferred to the cloth support during the production of the transdermal preparation, If the support is excessively stretched, there is a problem that stacking failure or shrinkage occurs after stacking.
Further, when the fabric support is excessively extended, there is a problem that the support is extended during application and cannot be properly attached to the skin, and the adhesive exudes from the texture of the support during storage.

In order to solve the above problems, for example,
Japanese Unexamined Patent Publication (Kokai) No. 52-99375 discloses a plaster using a base fabric which is obtained by integrating a fiber integrated sheet and a relatively coarse woven fabric by punching and then hot pressing.

Further, for example, in JP-A-62-40420, an anti-inflammatory analgesic tape agent using a flexible plastic film, a woven fabric and a non-woven fabric or a flexible plastic film, a woven fabric and a non-woven fabric as a support. Is disclosed.

Further, for example, Japanese Patent Application Laid-Open No. 2-212419 discloses a patch for disease treatment which uses a laminate having a porous film laminated on one surface of a plastic film as a support.

Further, for example, Japanese Patent Laid-Open No. 2-212423.
The publication discloses an anti-inflammatory / analgesic patch using a laminate in which a stretchable porous body is laminated on one surface of a plastic film as a support.

However, in any of the above-mentioned methods, even though the support can be provided with air permeability and moisture permeability, even if the extensibility is insufficient or the air permeability, moisture permeability and extensibility are satisfied, However, there is a problem that it is difficult to provide at low cost.

[0012]

SUMMARY OF THE INVENTION The present invention has been made to solve the above problems, and an object thereof is to prevent the lamination of the support and the pressure-sensitive adhesive from being defective and the support to be deformed at the time of application. An object of the present invention is to provide a tape preparation which has breathability and moisture permeability, has excellent skin followability, and does not exude an adhesive from the cloth of a support during production, storage and application.

[0013]

The tape preparation of the present invention comprises:
In a tape preparation having a pressure-sensitive adhesive layer containing a drug on one side of a support, the support is formed from a warp knit with a basis weight of 5 to 400 denier and a basis weight of 10 to 600 g / m ^2. The stretch ratio in the direction in which the stretchability of the knit is maximum is 1 per 30 mm width under a load of 2 kg.
The stretch ratio in the direction perpendicular to the direction in which the stretchability of the knit is maximum is in the range of 100 to 140% per 30 mm width under a load of 2 kg.

The present invention will be described in detail below. The support used in the present invention is formed of a warp knit made of fiber. The fiber may be any one that does not impair the performance of the tape preparation, and examples thereof include cellulose acetate, ethyl cellulose, polyethylene terephthalate, vinyl acetate-vinyl chloride copolymer, polyamide,
Examples thereof include ethylene-vinyl acetate copolymer, plasticized polyvinyl chloride, polyethylene, and polyvinylidene chloride. Among these fibers, polyethylene terephthalate is particularly preferable because it has the properties as a support such as drug non-migration property, chemical resistance, moisture resistance, dimensional stability, and dyeability, and is relatively inexpensive.

When the denier number of the above fiber is small, the adhesive easily exudes from the texture of the support, and when it is large, the followability to the skin is insufficient.
It is limited to 0 denier, preferably 5-250 denier.

The support is required to have excellent extensibility in one direction in order to give the following property to the skin, and a warp knit made of the above fiber is used.
The warp knit has a directional extension rate, and the extension rate is minimized in the direction perpendicular to the direction in which the extension rate is maximum. As the warp knit, for example, denby tricot knitting, tricot knitting, satin knitting, atlas knitting, plain knitting,
Rim knitting, pearl knitting, double-sided knitting, and the like are preferable, and among these, denby tricot knitting and tricot knitting are more preferable because they are particularly rich in unidirectional extensibility.

When the expansion ratio of the warp knit is small, the conformability to the skin is insufficient, and when it is large, lamination failure between the support and the pressure-sensitive adhesive layer or deformation at the time of sticking occurs, so that the expansion ratio is maximized. 30m under 2kg load
It is limited to 140 to 500%, preferably 150 to 250% per m width. Further, the extension rate of the warp knit, in the direction perpendicular to the direction in which the extension rate is maximum,
It is limited to 100 to 140%, preferably 110 to 130% per 30 mm width under a load of 2 kg.

When the basis weight of the warp knit used in the present invention is small, the pressure-sensitive adhesive easily exudes from the support, and when it is large, the support of the support on the skin is insufficient, so that the weight is 40 to 600 g / m ² . It is limited and is preferably 60 to 400 g / m ² .

In the present invention, a pressure-sensitive adhesive layer containing a drug and having adhesiveness at room temperature is formed on one surface of the support. The pressure-sensitive adhesive used in the pressure-sensitive adhesive layer is not particularly limited as long as it has a pressure-sensitive adhesive property that can be adhered to the skin at room temperature for a long time, and examples thereof include acrylic-based, rubber-based, and silicone-based adhesives. Adhesives are preferred.

The pressure-sensitive adhesive used in the present invention has a molecular weight of 100,000 or more in terms of polystyrene-reduced weight average molecular weight as measured by GPC, because the smaller the molecular weight, the more exudates from the stitches.

As the above-mentioned acrylic pressure-sensitive adhesive, in particular, a copolymer of an aliphatic alcohol having 4 to 18 carbon atoms and a (meth) acrylic acid alkyl ester obtained from (meth) acrylic acid, vinylpyrrolidone and other functional monomers are used. Polymers are preferred.

Examples of the (meth) acrylic acid alkyl ester include (meth) acrylic acid-n-butyl,
Isobutyl (meth) acrylate, hexyl acrylate,
Octyl (meth) acrylate, isooctyl (meth) acrylate, decyl (meth) acrylate, isodecyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, 2-ethylhexyl acrylate, etc. Can be mentioned.

Examples of the above-mentioned functional monomer include monomers having a hydroxyl group, a carboxyl group, an amino group and an amide group.

Examples of the monomer having a hydroxyl group include hydroxyalkyl (meth) acrylates such as 2-hydroxyethyl (meth) acrylate and hydroxypropyl (meth) acrylate.

Examples of the monomer having a carboxyl group include α, β-unsaturated carboxylic acid such as (meth) acrylic acid; maleic acid monoalkyl ester such as butyl maleate; (anhydrous) maleic acid, fumaric acid and croton. Acid etc. are mentioned.

Examples of the monomer having an amino group include dimethylaminoethyl acrylate and the like.

Examples of the monomer having an amide group include (meth) acrylamides such as acrylamide, dimethylacrylamide and dimethylacrylamide; alkyl ether methylol (meth) acrylamides such as butoxymethyl acrylamide and ethoxymethyl acrylamide; and diacetone acrylamide. To be

As functional monomers other than the above, vinyl acetate, vinyl alcohol, styrene, α-methylstyrene, vinyl chloride, acrylonitrile, ethylene, propylene, butadiene and the like can be used.

Since the adhesiveness decreases when the amount of alkyl (meth) acrylate in the acrylic adhesive decreases, it is preferable to contain 50% by weight or more, more preferably 65% by weight or more as a copolymerization component. .

If necessary, a polyfunctional monomer copolymerizable with other monomers may be added to the acrylic pressure-sensitive adhesive as long as it does not adversely affect the drug release property and the mildness. Good. This polyfunctional monomer causes only slight cross-linking between the resulting copolymers, increasing the internal cohesive strength of the adhesive. This internal cohesive force almost eliminates the so-called adhesive residue phenomenon that occurs when the transdermal absorption preparation is peeled off, regardless of the properties of the applied skin and the amount of perspiration.

Examples of the polyfunctional monomer include, for example,
Di (meth) acrylic acid alkyl ester, tri (meth)
Examples thereof include acrylic acid alkyl esters and tetra (meth) acrylic acid alkyl esters. Specifically, di (meth) acrylic acid obtained by reacting poly (methylene glycols) such as hexamethylene glycol and octamethylene glycol with (meth) acrylic acid. ) Acrylic acid: Tri (meth) acrylic acid such as trimethylolpropane tri (meth) acrylic acid and glycerin (meth) acrylic acid, and tetra (meth) acrylic acid such as pentaerythritol tetra (meth) acrylic acid. Two or more kinds of these polyfunctional monomers may be used in combination.

If the compounding amount of the above-mentioned polyfunctional monomer is small, the effect of improving the internal cohesive force due to the crosslinking of the pressure-sensitive adhesive is not obtained, and if it is large, the pressure-sensitive adhesive is apt to cause gelation, which adversely affects the diffusion and release of the drug. 0.005 to 0.5% by weight is preferable with respect to all the monomers mixed in the adhesive.

If necessary, a tackifier may be added to the acrylic pressure-sensitive adhesive in order to impart tackiness. Examples of the tackifier include rosin-based resins, terpene-based resins, petroleum resins, coumarone-indene resins, terpene-phenol resins, and the like, preferably rosin-based resins such as hydrogenated rosin esters.

The acrylic pressure-sensitive adhesive is prepared, for example, by mixing the above-mentioned monomers in the presence of a polymerization initiator and carrying out solution polymerization.

Examples of the rubber-based pressure-sensitive adhesive used in the present invention include rubber elastic bodies such as natural rubber, styrene-isoprene-styrene block copolymer, polyisoprene, polybutene, polyisobutylene, ethylene-vinyl acetate copolymer. The base polymer is used as the base polymer. The rubber-based pressure-sensitive adhesive includes 100 parts by weight of the base polymer, 20 to 200 parts by weight of the tackifying resin, and if necessary, a softening agent such as liquid polybutene, mineral oil, lanolin, liquid polyisoprene, and liquid polyacrylate. Be compounded.

Examples of the silicone-based pressure-sensitive adhesive used in the present invention include those containing polydimethylsiloxane as a main component.

The acrylic, rubber and silicone pressure-sensitive adhesives used in the present invention may be blended with a plasticizer, a filler, an antioxidant and the like, if necessary.

Drug used in the present invention (physiologically active substance)
As, is not particularly limited as long as it is absorbed from the skin, for example, antipyretic anti-inflammatory analgesics, steroidal anti-inflammatory agents, vasodilators, hypertensive / arrhythmic agents, antihypertensive agents, antitussive expectorants, Antitumor agent, local anesthetic, hormone agent,
Asthma / nasal allergy treatment agent, antihistamine, anticoagulant, antispasmodic agent, cerebral circulation / metabolic agent, antidepressant / anxiety agent,
Vitamin D preparations, hypoglycemic agents, anti-ulcer agents, hypnotics, antibiotics and the like can be mentioned. Furthermore, topical drugs such as antipyretic anti-inflammatory analgesics and steroidal anti-inflammatory agents, which are also applied to flexion sites such as joints, are suitable. These agents may be used alone or in combination of two or more kinds.

Examples of the antipyretic and anti-inflammatory analgesics include indomethacin, salicylic acid, aspirin, acetaminophen, diclofenac sodium, ibuprofen, sulindac, naproxen, flufenamic acid, ibufenac, fenbufen, alclofenac,
Examples include phenylbutazone, mefenamic acid, bendazac, piroxicam, flurbiprofen, pentazocine, buprenorphine hydrochloride, butorphanol tartrate and the like.

Examples of steroidal anti-inflammatory agents include:
Examples thereof include hydrocortisone, prednisolone, fluocinolone acetonide, fludroxycortide, methylprednisolone, hydrocortisone acetate, triamcinolone acetonide, dexamethasone, betamethasone acetate, diflucortron valerate, clobetasol propionate, and fluocinonide.

Examples of the vasodilator include diltiazem, diltiazem hydrochloride, verapamil, pentaerythritol tetranitrate, dipyridamole, isosorbide dinitrate, nifedipine, nitroglycerin and the like.

Examples of the antihypertensive / arrhythmic agent include propanolol, atenolol, pindolol, quinidine sulfate, azimarin, alprenol hydrochloride, metoprolol tartrate, nadolol, timolol maleate, disopyramide and the like.

Examples of the antihypertensive agent include clonidine hydrochloride, captopril, prazosin hydrochloride, penbutol sulfate sulfate, guanabenz acetate, guanfacine hydrochloride, bunazosin hydrochloride, elanpril maleate, arotinolol hydrochloride and bunitrolol hydrochloride.

Examples of the antitussive and expectorant include procateol hydrochloride, terbutaline sulfate, fenoterol hydrobromide, tulobuterol hydrochloride, ambroxol hydrochloride, pirbuterol hydrochloride, mabuterol hydrochloride, clenbuterol hydrochloride, trimetoquinol hydrochloride, formo fumarate. Examples include terol.

Examples of the antitumor agent include 5-fluorouracil, 1- (2-tetrahydrofuryl) -5-fluorouracil, mitomycin-C and the like, and examples of the local anesthetic include procaine, lidocaine, benzocaine and the like. Can be mentioned.

The hormonal agents include, for example, steroid hormones such as estrogen, estradiol, testosterone, progesterone and prostaglandin,
Examples include peptide hormones such as insulin.

Examples of therapeutic agents for asthma / nasal allergy include ketotifen fumarate, azelastine hydrochloride, sodium chromoglylate, and the like, and antihistamines include cycloheptazine hydrochloride, diphenhydramine hydrochloride, phenbenzamine, mequitazine, etc. To be

Examples of the anticoagulant include heparin and the like, and examples of the antispasmodic include scopolamine, clofluperol and the like.

Examples of the cerebral circulation / metabolic agent include vinpocetine, flunarizine hydrochloride, nicardipine hydrochloride, brovincamin fumarate, dihydroergotoxine mesylate, ifenprodil tartrate, isoxuprine hydrochloride and the like.

Examples of the antidepressant / anti-anxiety agents include maprotiline hydrochloride, etizolam, diazepam, bromazepam, amitriptyline hydrochloride, mianserin hydrochloride and the like. Examples of vitamin D preparations include alfacalcidol, ergocalciferol and the like. Can be mentioned.

Examples of the hypoglycemic agent include glibenclamide, gliclatide and the like, and examples of the anti-ulcer agent include clevobride malate, famotidine, glycopyrronium bromide and the like.

Examples of sleep agents include phenobarbital and amobarbital, and examples of antibiotics include:
For example, tetracycline, chloramphenicol and the like can be mentioned.

The content of the above-mentioned drug varies depending on the type of drug, the purpose of use of the tape preparation, etc., but if it increases, the drug will be deposited in the pressure-sensitive adhesive layer or the adhesiveness will decrease.
0.1 to 30% by weight is preferable. The thickness of the pressure-sensitive adhesive layer varies depending on the type and content of the drug and is not particularly limited, but is usually preferably 10 to 200 μm, more preferably 20 to 100 μm.

As a method for producing the above tape preparation,
For example, it can be obtained by preparing a solution or dispersion containing an adhesive, a drug, etc., coating this on the support, and drying. Further, instead of using the above solution or dispersion, a method of heating and dissolving a mixture of an adhesive, a drug, etc. and laminating this on a support is also adopted. Furthermore, coating the above solution, dispersion or dissolved substance on a suitable release paper,
A method of drying and bringing the support into close contact therewith is also used.

The above-mentioned release paper is used for the purpose of protecting the pressure-sensitive adhesive layer. For example, a polyethylene terephthalate film, a polyethylene-coated high-quality paper, a polyolefin-coated glassine paper, a polypropylene film, or the like with a silicone release treatment on one side is used. The thickness is usually preferably 500 μm or less, and more preferably 20 to 200 μm.

The shape of the tape preparation can be freely selected from a sheet shape, a band shape, a patch shape, a roll shape, and the like.

[0057]

EXAMPLES Examples of the present invention will be described below. (Example 1) [Preparation of acrylic pressure-sensitive adhesive] 2-ethylhexyl acrylate (75% by weight (187.5 parts by weight)) and vinylpyrrolidone (25% by weight) (62.5 parts by weight) were charged in a separable flask and polymerized. A solution was obtained by adding 250 parts by weight of ethyl acetate so that the initial monomer concentration was 50% by weight. This solution was heated to 80 ° C. under a nitrogen atmosphere, and a solution of 1 part by weight of lauroyl peroxide as a polymerization initiator dissolved in 100 ml of ethyl acetate was added little by little to carry out a polymerization reaction for 8 hours to obtain a solid content. An ethyl acetate solution of an acrylic adhesive having a concentration of 37% by weight and having an adhesive property at room temperature was obtained.

[Preparation of Drug-Containing Pressure-Sensitive Adhesive Solution] A drug-containing pressure-sensitive adhesive solution was prepared by dissolving 15% by weight of aspirin as a drug in 85% by weight of the solid content of the acrylic pressure-sensitive adhesive solution.

[Preparation of Tape Formulation] The above-mentioned drug-containing pressure-sensitive adhesive solution was coated on a release paper on which a polyethylene terephthalate film having a thickness of 35 μm was subjected to silicone release treatment, and then dried at 60 ° C. for 30 minutes to give a thickness of 80 μm. A drug-containing pressure-sensitive adhesive layer was formed. Next, Denon tricot knitted with 20 denier polyester fiber, and basis weight 45 g
Using a knit of / m ² as a support, the drug-containing pressure-sensitive adhesive layer was transferred while stretching with a slight tension in the direction of the smallest extensibility of the support to prepare a tape preparation.

[Evaluation / Measurement of Performance] 1) Measurement of Support Extension Rate Two kinds of samples (size: 30 × 120 mm) were prepared by cutting the support alone as follows, and the long side of each sample was prepared. Directional marks were provided at intervals of 100 mm. (A) Cut so that the direction with the greatest extensibility becomes the long side. (B) Cut so that the longest side is in the direction perpendicular to the direction of greatest extensibility. Then, the sample was set in a rheometer, the gauge length (C) [mm] at the time when a load of 2 kg was applied, and the extension rate was calculated from the following formula, and the results are shown in Table 1. Extension rate (%) = (C / 100) x 100

2) Evaluation of skin followability The tape preparation prepared above was cut into 50 × 100 mm and applied to an elbow joint, and the skin followability was sensory evaluated according to the following 4 criteria. ⊚: When applied for 6 hours without peeling or wrinkling and no discomfort when bending or stretching the joint. ◯: When there is no peeling or wrinkling after applying for 6 hours. Δ: When there is peeling, wrinkling, or discomfort when the joint is bent or stretched after being applied for 6 hours. ×: When the product was applied for 6 hours, peeled off or wrinkled, and there was a clear discomfort when the joint was bent or stretched.

3) Evaluation of Exudation Property of Pressure-sensitive Adhesive The tape preparation prepared above was cut into 50 × 100 mm and attached to the elbow joint. Next, after bending and stretching the elbow joint 20 times, the surface of the support was strongly pressed by the finger pad, and the presence or absence of exudation of the adhesive was evaluated. The results are shown in Table 1.

4) Primary irritation test of rabbit skin Rabbits (New Zealand White, male, 15 weeks old or older) were shaved using an electric clipper and an electric shaver, and a circular transdermal absorption preparation with a diameter of 20 mm was applied to the back skin. Was pasted. Thirty minutes after peeling after sticking for 24 hours, the skin irritation state of the stuck part was evaluated according to the following criteria. 0: no erythema, 1: very slight erythema was observed, 2:
Clear erythema was observed, 3: moderate to strong erythema was observed, and 4: erythema with bleeding was observed. This test was conducted on 6 rabbits, and the average value of 6 rabbits is shown in Table 1.

5) Hairless mouse skin permeation test Hairless mice (8 weeks old, male) were sacrificed by cervical dislocation, and then the skin was immediately peeled off to remove subcutaneous fat.
A m × 5 cm extracted test piece was obtained. The test piece was set in a Franz cell with the front side facing upward, and a circular tape preparation having a diameter of 20 mm was attached to the skin front side.
Fill the receptor tank with phosphate buffer pH 7.2, 3
The drug was allowed to stand in a constant temperature bath at 7 ° C., and after 24 hours, the amount of the drug permeated into the receptor solution was quantified to obtain the drug permeation amount. This drug permeation amount was converted into 1 cm ² of the excised test piece to obtain skin permeability.

(Example 2) A knit obtained by tricot knitting 250 denier polyester fiber (unit weight: 400 g /
After the tape preparation was prepared in the same manner as in Example 1 except that m ² ) was used as the support, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1.

Example 3 Example 2 was repeated except that 7% by weight of indomethacin was contained in the adhesive layer as a drug.
After the tape preparation was prepared in the same manner as above, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1.

(Example 4) A knit obtained by atlas-knitting a polyester fiber of 350 denier (weight per unit area: 520 g / m 2)
After the tape preparation was prepared in the same manner as in Example 1 except that ² ) was used as the support, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1.

(Example 5) As a drug, piroxicam 5
A tape preparation was prepared in the same manner as in Example 4 except that the pressure-sensitive adhesive layer was contained in an amount of 1% by weight, and then the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1. It was

(Comparative Example 1) Deny tricot knit of 20 denier polyester fiber (weight 30
After the tape preparation was prepared in the same manner as in Example 1 except that g / m ² ) was used as the support, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1. It was

(Comparative Example 2) A knit obtained by tricot knitting 450 denier polyester fibers (unit weight: 700 g /
After the tape preparation was prepared in the same manner as in Example 1 except that m ² ) was used as the support, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1.

Comparative Example 3 A tape preparation was prepared in the same manner as in Example 1 except that a nonwoven fabric (thickness 100 μm) obtained by needle punching 40 denier polyester fiber was used as the support, and then Example 1 was used. The performance was evaluated and measured in the same manner as in, and the results are shown in Table 1.

Comparative Example 4 A tape preparation was prepared in the same manner as in Example 1 except that a laminated film (thickness: 35 μm) obtained by laminating a polyethylene terephthalate film and an ethylene-vinyl acetate copolymer film was used as a support. After the preparation, the same performance evaluation and measurement as in Example 1 were performed, and the results are shown in Table 1.

[0073]

[Table 1]

[0074]

EFFECT OF THE INVENTION The tape preparation of the present invention has breathability or moisture permeability, is excellent in skin followability, and is free from adhesive laminating failure and deformation during application, and during preparation, storage and application. , The adhesive does not seep out from the stitches of the support. Further, the tape preparation of the present invention has no discomfort during application and does not cause skin irritation.

Claims (1)

[Claims] 1. A tape preparation having a pressure-sensitive adhesive layer containing a drug provided on one surface of a support, wherein the support has 5 to 4 parts.
Made from 00 denier fiber, weight 10-600
It is formed from a warp knit of g / m ² and has an extension rate of 30 m under a load of 2 kg in the direction in which the extensibility of the knit is maximized.
A tape preparation characterized in that it is 140 to 500% per m width, and the extension ratio in the direction perpendicular to the direction in which the extensibility of the knit is the maximum is 100 to 140% per 30 mm width under a load of 2 kg. .